e Department of Gastroenterology, University of Maryland School of Medicine, MD, USA (Hassan Ghoz) Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with gastrointestinal (GI) adverse effects, but real-world evidence about their incidence in patients with functional GI disorders is limited
Retatrutide pancreatitis is a recognized side effect that most patients experience temporarily during the first weeks of treatment
It slows digestion and communicates directly with the brain to lower our desire to eat
These programs often incorporate GLP-1 therapy as part of a broader strategy, combining medical expertise with lifestyle modifications
Perera VR, newton GL, Pogliano K
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes